Representing Sortina Pharma at Brain Tumour Research Novel Therapeutics Accelerator Review Meeting in Edinburgh

Written By Sara Rhost

Sortina Pharma was at the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) review meeting in Edinburgh in May 2025 to meet 21 global experts in therapeutic development and neuro-oncology to evaluate and advance the progress of our promising new drug candidate for brain tumours.

Read more about BTR-NTA here

Sara Rhost
Previous

Sortina Pharma Joins Nordic Mentor Network for Entrepreneurship (NOME)
Next

Granted European patent